A Phase 3 interventional study of GTx-024 and placebo in Muscle Wasting and Non Small Cell Lung Cancer, sponsored by GTx. Completed at 27 sites in United States. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2016-03-03.
Sponsored by GTx · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 115 studies in Muscular Atrophy with a site in United States — 15 open to participants now, 26 under way, 2 of them phase 3. Muscular Atrophy · United States.
Among the 115 studies in Muscular Atrophy with a site in United States, this one is the 3rd largest by enrollment of the 105 interventional ones that give a count, is one of 6 that started in 2011, is one of 10 in phase 3, and was the 16th registered.
413 studies on the registry are indexed under Muscular Atrophy; 77 are open to participants now.
Browse Muscular Atrophy studies →15 of the 115 studies in Muscular Atrophy with a site in United States are open now. Recruiting first, the newest first:
Sam Houston State University · Sites in United States
Ages 18–35 · Women only · Healthy volunteers
Brigham Young University · Sites in United States
Ages 18+ · Healthy volunteers
University of Utah · Sites in United States
Ages 60+ · Healthy volunteers
Michael C Willey · Sites in United States
Ages 65+
Tufts Medical Center · Sites in United States
Ages 18–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 52 Muscular Atrophy studies recruiting now, 25 (48%) set no upper age limit and 13 (25%) stop at 75 or younger; 4 take children under 18; 17 take healthy volunteers.
This study: 30 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
115 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 27 · Phase 3 13 · Phase 4 4
First in 1995; this study’s year is marked. 6 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 321 is above the median of 40 across 327 interventional studies indexed under Muscular Atrophy.
Median enrollment 40 across the 105 interventional studies, 61 across the 9 observational. Of the 81 that completed or were terminated, 41 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 115 have an industry lead sponsor. The 10 most frequent:
GTx is the lead sponsor of 19 studies on the registry; none are open to participants now.
GTx has 3 studies filed under Muscular Atrophy — fewer than ten, so there is no comparison to draw.
13 of the studies in Muscular Atrophy with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06050668Michael C WilleyEssential Amino Acid Supplementation for Femoral Fragility Fractures | 2026-12 |
| NCT04809714University of Alabama at BirminghamThe Role of Blood Flow Restriction Therapy in Postoperative Elderly Patients With Hip Fracture | 2026-12-13 |
| NCT07843095Sam Houston State UniversityProtein Supplementation During Luteal Phase to Stop Protein Degradation | 2026-12-17 |
| NCT06136221University of PennsylvaniaTesting LiverWatch, a Home-Based Remote-Monitoring Intervention for Advanced Liver Disease | 2026-12-30 |
| NCT03332238Hospital for Special Surgery, New YorkStromal Vascular Fraction Cell Therapy to Improve the Repair of Rotator Cuff Tears | 2026-12-31 |
Add all 13 to your calendar (.ics) → With an account.
Among the 115 studies in Muscular Atrophy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if the investigational drug GTx-024 can help subjects with non-small cell lung cancer increase physical function and maintain or gain muscle, also called "lean body mass".
This is a randomized, double-blind, placebo controlled, multicenter, multinational efficacy and safety study in subjects with non small cell lung cancer (NSCLC). Subjects will be evenly randomized to placebo or GTx-024 prior to initiation of first line chemotherapy. The primary efficacy analysis will be based on total lean body mass and physical function.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
subject will receive GTx-024 treatment for the duration of the trial
Drug: GTx-024
subject will receive placebo for the duration of the trial
Drug: placebo
subjects will be randomized to receive GTx-024 for the full duration of the trial.
subject will receive placebo for the duration of the trial
Physical Function
Measure is the percentage of subjects at day 84 with stair climb power change \>=10% from their baseline value.
Time frame: Day 84
Lean Body Mass
Measure is the percentage of subjects at day 84 with lean body mass change \>=0% from their baseline value.
Time frame: Day 84
| Milestone | GTx-024 | Placebo |
|---|---|---|
| Started | 160 | 161 |
| Completed | 109 | 107 |
| Not completed | 51 | 54 |
Measure is the percentage of subjects at day 84 with stair climb power change \>=10% from their baseline value.
| percentage of subjects | GTx-024 | Placebo |
|---|---|---|
| Physical Function | 29.4 (22.4 to 37.1) | 24.2 (17.8 to 31.6) |
Measure is the percentage of subjects at day 84 with lean body mass change \>=0% from their baseline value.
| percentage of subjects | GTx-024 | Placebo |
|---|---|---|
| Lean Body Mass | 41.9 (34.1 to 49.9) | 30.4 (23.4 to 38.2) |
Collected over 1 year, 7 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GTx-024 | — | 56/160 (35%) | 141/160 (88.1%) |
| Placebo | — | 60/161 (37.3%) | 144/161 (89.4%) |
| Event | GTx-024 | Placebo |
|---|---|---|
| Disease ProgressionGeneral disorders | 19/160 | 16/161 |
| PneumoniaInfections and infestations | 6/160 | 4/161 |
| DehydrationMetabolism and nutrition disorders | 1/160 | 6/161 |
| AnaemiaBlood and lymphatic system disorders | 4/160 | 5/161 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 4/160 | 2/161 |
| Respiratory FailureRespiratory, thoracic and mediastinal disorders | 2/160 | 4/161 |
| NeutropeniaBlood and lymphatic system disorders | 3/160 | 4/161 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/160 | 2/161 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 3/160 | 2/161 |
| Pulmonary HaemorrhageRespiratory, thoracic and mediastinal disorders | 0/160 | 3/161 |
| Event | GTx-024 | Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 57/160 | 52/161 |
| AlopeciaSkin and subcutaneous tissue disorders | 54/160 | 52/161 |
| AnaemiaBlood and lymphatic system disorders | 46/160 | 44/161 |
| AstheniaGeneral disorders | 33/160 | 20/161 |
| Disease ProgressionGeneral disorders | 22/160 | 32/161 |
| NeutropeniaBlood and lymphatic system disorders | 20/160 | 30/161 |
| VomitingGastrointestinal disorders | 29/160 | 26/161 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 27/160 | 22/161 |
| Decreased AppetiteMetabolism and nutrition disorders | 11/160 | 27/161 |
| DiarrhoeaGastrointestinal disorders | 18/160 | 24/161 |
Subjects included in the Full Analysis Set
| Age, Continuous(years) | GTx-024 | Placebo | Total |
|---|---|---|---|
| Median | 60.5 (36 to 84) | 62.0 (34 to 88) | 61.0 (34 to 88) |
| Sex: Female, Male(Participants) | GTx-024 | Placebo | Total |
|---|---|---|---|
| Female | 43 | 46 | 89 |
| Male | 117 | 115 | 232 |
The record gives a start of Jul 2011, a primary completion of May 2013 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2016, 2 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ostarine
GTx